SCHEMBL4928646

SCHEMBL4928646

Cc1cc(-c2ccccc2OCCN2CCCC2)ccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 11/20 0.44
AKT1 P31749 10/20 0.41
LRRK2 Q5S007 1/20 0.41
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KIT P10721 1/20 0.39
KDR P35968 1/20 0.39
FLT3 P36888 1/20 0.39
TNK2 Q07912 1/20 0.38
ESR1 P03372 2/20 0.37
ESR2 Q92731 2/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1791682 0.94 RPS6KB1 (0.44) RPS6KB1AKT1LRRK2TDP1KDM4E
SCHEMBL1791664 0.89 RPS6KB1 (0.44) RPS6KB1AKT1LRRK2KDM4ESMN1; SMN2
SCHEMBL1788327 0.88 KDM4E (0.42) RPS6KB1AKT1LRRK2KDM4EKIT
SCHEMBL4928639 0.86 LTA4H (0.45) RPS6KB1AKT1SMN1; SMN2TNK2MEN1
SCHEMBL1791899 0.84 USP2 (0.43) RPS6KB1AKT1LRRK2KDM4EFLT3
SCHEMBL1792161 0.82 RPS6KB1 (0.41) RPS6KB1AKT1LRRK2KDM4ESMN1; SMN2
SCHEMBL1790594 0.82 RPS6KB1 (0.41) RPS6KB1AKT1TNK2MEN1KMT2A
SCHEMBL1791763 0.81 RPS6KB1 (0.42) RPS6KB1AKT1LRRK2KDM4ESMN1; SMN2
SCHEMBL1792648 0.81 RPS6KB1 (0.42) RPS6KB1AKT1LRRK2ESR1ESR2
SCHEMBL1793930 0.80 LTA4H (0.45) RPS6KB1AKT1TNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076338-B2 Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation EXELIXIS, INC. (US) 2011-12-13 US disclosed
US-20080076774-A1 Kinase Modulators and Methods of Use EXELIXIS, INC. (US) 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076774-A1 Kinase Modulators and Methods of Use AKT3, RPS6KA3, CDK3 RPS6KB1 13/4885AKT1 6/4885LRRK2 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.